Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$39.5 million.

  • Inhibikase Therapeutics' Net Cash Flow fell 171649.0% to -$39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 36782.75%. This contributed to the annual value of $47.3 million for FY2024, which is 229425.16% up from last year.
  • Inhibikase Therapeutics' Net Cash Flow amounted to -$39.5 million in Q3 2025, which was down 171649.0% from $4.3 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Net Cash Flow high stood at $55.6 million for Q4 2024, and its period low was -$39.5 million during Q3 2025.
  • Over the past 5 years, Inhibikase Therapeutics' median Net Cash Flow value was -$2.2 million (recorded in 2024), while the average stood at $1.3 million.
  • The largest annual percentage gain for Inhibikase Therapeutics' Net Cash Flow in the last 5 years was 69463218.28% (2021), contrasted with its biggest fall of 8167488.7% (2021).
  • Inhibikase Therapeutics' Net Cash Flow (Quarter) stood at -$4.1 million in 2021, then soared by 134.34% to $1.4 million in 2022, then crashed by 504.95% to -$5.7 million in 2023, then soared by 1075.7% to $55.6 million in 2024, then tumbled by 171.02% to -$39.5 million in 2025.
  • Its Net Cash Flow stands at -$39.5 million for Q3 2025, versus $4.3 million for Q2 2025 and $17.0 million for Q1 2025.